LABORATOIRES EUROMEDIS(EPA:ALEMG) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 4 out of 10 to ALEMG. ALEMG was compared to 55 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and the financial health of ALEMG get a neutral evaluation. Nothing too spectacular is happening here. ALEMG has a decent growth rate and is not valued too expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

ALEMG had positive earnings in the past year.

The reported net income has been mixed in the past 5 years: ALEMG reported negative net income in multiple years.

The reported operating cash flow has been mixed in the past 5 years: ALEMG reported negative operating cash flow in multiple years.

1.2 Ratios

The Return On Assets of ALEMG (27.66%) is better than 98.18% of its industry peers.

Looking at the Return On Equity, with a value of 57.02%, ALEMG belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	27.66%
ROE	57.02%
ROIC	N/A

ROA(3y)7.18%

ROA(5y)7.85%

ROE(3y)15.48%

ROE(5y)16.44%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Profit Margin, with a value of 24.05%, ALEMG belongs to the top of the industry, outperforming 90.91% of the companies in the same industry.

ALEMG's Profit Margin has improved in the last couple of years.

ALEMG has a worse Gross Margin (31.89%) than 80.00% of its industry peers.

ALEMG's Gross Margin has declined in the last couple of years.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	24.05%
GM	31.89%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3Y48.68%

PM growth 5YN/A

GM growth 3Y-2.88%

GM growth 5Y-2.61%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALEMG does not have a ROIC to compare to the WACC, probably because it is not profitable.

ALEMG has less shares outstanding than it did 1 year ago.

The number of shares outstanding for ALEMG has been reduced compared to 5 years ago.

ALEMG has a better debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of 1.68, we must say that ALEMG is in the distress zone and has some risk of bankruptcy.

ALEMG's Altman-Z score of 1.68 is in line compared to the rest of the industry. ALEMG outperforms 49.09% of its industry peers.

A Debt/Equity ratio of 0.41 indicates that ALEMG is not too dependend on debt financing.

ALEMG has a Debt to Equity ratio of 0.41. This is comparable to the rest of the industry: ALEMG outperforms 54.55% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.41
Debt/FCF	N/A
Altman-Z	1.68

ROIC/WACCN/A

WACC6.12%

2.3 Liquidity

ALEMG has a Current Ratio of 3.47. This indicates that ALEMG is financially healthy and has no problem in meeting its short term obligations.

With a decent Current ratio value of 3.47, ALEMG is doing good in the industry, outperforming 78.18% of the companies in the same industry.

A Quick Ratio of 2.57 indicates that ALEMG has no problem at all paying its short term obligations.

ALEMG has a Quick ratio of 2.57. This is in the better half of the industry: ALEMG outperforms 80.00% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.47
Quick Ratio	2.57

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ALEMG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 339.63%, which is quite impressive.

ALEMG shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -15.45% yearly.

ALEMG shows a small growth in Revenue. In the last year, the Revenue has grown by 5.58%.

The Revenue for ALEMG have been decreasing by -20.58% on average. This is quite bad

EPS 1Y (TTM)339.63%

EPS 3Y-15.45%

EPS 5YN/A

EPS Q2Q%89.97%

Revenue 1Y (TTM)5.58%

Revenue growth 3Y-43.96%

Revenue growth 5Y-20.58%

Sales Q2Q%-26.01%

3.2 Future

Based on estimates for the next years, ALEMG will show a very strong growth in Earnings Per Share. The EPS will grow by 22.41% on average per year.

ALEMG is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -11.48% yearly.

EPS Next Y60%

EPS Next 2Y31.67%

EPS Next 3Y22.41%

EPS Next 5YN/A

Revenue Next Year5.19%

Revenue Next 2Y6.36%

Revenue Next 3Y-11.48%

Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 0.90, which indicates a rather cheap valuation of ALEMG.

ALEMG's Price/Earnings ratio is rather cheap when compared to the industry. ALEMG is cheaper than 100.00% of the companies in the same industry.

ALEMG's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 29.35.

A Price/Forward Earnings ratio of 8.89 indicates a reasonable valuation of ALEMG.

Based on the Price/Forward Earnings ratio, ALEMG is valued cheaper than 89.09% of the companies in the same industry.

ALEMG is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.10, which is the current average of the S&P500 Index.

		Industry Rank	Sector Rank
PE	0.9
Fwd PE	8.89

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

A more expensive valuation may be justified as ALEMG's earnings are expected to grow with 22.41% in the coming years.

PEG (NY)0.01

PEG (5Y)N/A

EPS Next 2Y31.67%

EPS Next 3Y22.41%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ALEMG does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

LABORATOIRES EUROMEDIS

EPA:ALEMG (3/7/2025, 7:00:00 PM)

3.97

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)10-10 2024-10-10

Earnings (Next)04-24 2025-04-24/amc

Inst Owners4.63%

Inst Owner ChangeN/A

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap11.39M

Analysts37.14

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DP0%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	0.9
Fwd PE	8.89
P/S	0.22
P/FCF	N/A
P/OCF	N/A
P/B	0.52
P/tB	0.52
EV/EBITDA	N/A

EPS(TTM)4.42

EY111.34%

EPS(NY)0.45

Fwd EY11.24%

FCF(TTM)N/A

FCFYN/A

OCF(TTM)N/A

OCFYN/A

SpS18.22

BVpS7.69

TBVpS7.68

PEG (NY)0.01

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	27.66%
ROE	57.02%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	24.05%
GM	31.89%
FCFM	N/A

ROA(3y)7.18%

ROA(5y)7.85%

ROE(3y)15.48%

ROE(5y)16.44%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3Y48.68%

PM growth 5YN/A

GM growth 3Y-2.88%

GM growth 5Y-2.61%

F-ScoreN/A

Asset Turnover1.15

Health

		Industry Rank	Sector Rank
Debt/Equity	0.41
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.47
Quick Ratio	2.57
Altman-Z	1.68

F-ScoreN/A

WACC6.12%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)339.63%

EPS 3Y-15.45%

EPS 5YN/A

EPS Q2Q%89.97%

EPS Next Y60%

EPS Next 2Y31.67%

EPS Next 3Y22.41%

EPS Next 5YN/A

Revenue 1Y (TTM)5.58%

Revenue growth 3Y-43.96%

Revenue growth 5Y-20.58%

Sales Q2Q%-26.01%

Revenue Next Year5.19%

Revenue Next 2Y6.36%

Revenue Next 3Y-11.48%

Revenue Next 5YN/A

EBIT growth 1Y-86.02%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year163.64%

EBIT Next 3Y20.09%

EBIT Next 5YN/A

FCF growth 1YN/A

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1YN/A

OCF growth 3YN/A

OCF growth 5YN/A

LABORATOIRES EUROMEDIS (ALEMG.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens